How much cash does OnKure Therapeutics, Inc. generate?

OnKure Therapeutics, Inc. (OKUR) generated -$50.8M in operating cash flow over the trailing twelve months.

What is OnKure Therapeutics, Inc.'s free cash flow?

After $33.0K of capital expenditures, OnKure Therapeutics, Inc.'s free cash flow was -$50.8M over the trailing twelve months, up 6.9% year over year.

Where does OnKure Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from OnKure Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

OnKure Therapeutics, Inc. OKUR Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$15.16M+4.8%	-$13.5M+22.6%	-$14.7M-27.2%	-$15.39M-8.8%	-$15.93M-67.0%
Depreciation and amortization	$104K-11.9%	$104K-10.3%	$108K-5.3%	$117K+1.7%	$118K+3.5%
Stock-based compensation	$2.78M+1.3%	$3.02M+19.2%	$2.96M+3,745%	$2.91M+60.4%	$2.75M+2,465%
Amortization of debt issuance costs	——	——	——	——	——
Change in accounts payable	-$905K+46.1%	-$305K+97.2%	-$1.36M-141%	-$1.2M-116%	-$1.68M+3.5%
Change in other assets	-$281K+61.6%	——	——	-$326K-119%	-$731K-67.3%
Change in other liabilities	——	——	——	——	$40K—
Non-cash operating lease expense	$99K+5.3%	$98K+6.5%	$96K+153%	$95K+164%	$94K+154%
Change in operating lease liabilities	-$140K-7.7%	-$138K-8.7%	-$136K-157%	-$132K-159%	-$130K-160%
Net cash from operating activities	-$12.94M+7.6%	-$11.51M+50.7%	-$13.04M-22.3%	-$13.27M-105%	-$14.01M-31.8%
Capital expenditures	$5K-72.2%	$9K-40.0%	$6K-66.7%	$13K+30.0%	$18K+100%
Net cash from investing activities	-$5K+72.2%	-$9K-100%	-$6K+66.7%	-$13K-30.0%	-$18K-100%
Proceeds from issuance of debt	——	——	——	——	——
Proceeds from issuance of common stock	——	——	——	——	——
Net cash from financing activities	$146M+189,709%	$240K-99.8%	——	——	-$77K-870%
Net increase (decrease) in cash	$133.06M+1,044%	-$11.28M-111%	-$13.04M-22.2%	-$13.29M-2,060%	-$14.1M-32.7%
Operating lease liabilities	-$140K-7.7%	-$138K-8.7%	-$136K-157%	-$132K-159%	-$130K-160%
Other long-term liabilities	——	——	——	——	$40K—
Increase (Decrease) in Prepaid Expense and Other Assets	-$281K+61.6%	——	——	-$326K-119%	-$731K-67.3%
Operating lease right-of-use asset amortization	$99K+5.3%	$98K+6.5%	$96K+153%	$95K+164%	$94K+154%
Payment Of Reverse Recapitalization Transaction Costs	——	——	——	——	$40K-92.2%
Payments Of Stock Issuance Costs	——	——	——	——	$37K—
Sale of noncontrolling interest in subsidiary (Note 8)	——	——	——	——	——
Proceeds from issuance of common stock relating to employee stock plans	——	$60K—	$60K—	$60K—	$60K—
Assets Acquired In Connection With The Reverse Recapitalization	——	——	——	——	——
Concurrent Financing Issuance Costs Included In Accounts Payable	——	——	——	——	——
Concurrent Financing Issuance Costs Paid By Reneo Prior To Merger	——	——	——	——	——
Conversion Of Convertible Note Payable	——	——	——	——	——
Conversion Of Series C Preferred Stock	——	——	——	——	——
Increase Decrease In Operating Lease Liability	-$140K-7.7%	-$138K-8.7%	-$136K-157%	-$132K-159%	-$130K-160%
Other Liabilities Assumed In Connection With The Reverse Recapitalization	——	——	——	——	——
Private Placement Issuance Costs Included In Accounts Payable	$9.37M—	——	——	——	——
Private Placement Issuance Costs Included In Accrued Liabilities	$81K—	——	——	——	——
Private Placement Proceeds In Other Current Assets	-$4M—	——	——	——	——
Reverse Recapitalization Transaction Costs Included In Accounts Payable	——	——	——	——	——
Free cash flow	-$12.94M+7.7%	-$11.52M+50.7%	-$13.04M-22.1%	-$13.29M-105%	-$14.02M-31.8%
Free cash flow	-$12.94M+7.7%	-$11.52M+50.7%	-$13.04M-22.1%	-$13.29M-105%	-$14.02M-31.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does OnKure Therapeutics, Inc. generate?: OnKure Therapeutics, Inc. (OKUR) generated -$50.8M in operating cash flow over the trailing twelve months.
What is OnKure Therapeutics, Inc.'s free cash flow?: After $33.0K of capital expenditures, OnKure Therapeutics, Inc.'s free cash flow was -$50.8M over the trailing twelve months, up 6.9% year over year.
Where does OnKure Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from OnKure Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.